home / stock / edsa / edsa short
Short Information | Edesa Biotech Inc. (NASDAQ:EDSA)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 26,371 |
Total Actual Volume | 150,878 |
Short Trends | |
---|---|
Cover Days | 18 |
Short Days | 1 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 1,319 |
Average Short Percentage | 17.74% |
Is there a EDSA Short Squeeze or Breakout about to happen?
See the EDSA Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-26-2024 | $5.24 | $5.42 | $5.59 | $5.24 | 10,434 | 1,345 | 12.89% |
07-25-2024 | $4.76 | $5.11 | $5.11 | $4.76 | 7,763 | 935 | 12.04% |
07-24-2024 | $4.88 | $4.8 | $4.9199 | $4.775 | 8,707 | 600 | 6.89% |
07-23-2024 | $4.8568 | $4.6922 | $4.8568 | $4.6922 | 1,636 | 316 | 19.32% |
07-22-2024 | $4.8 | $4.63 | $4.8 | $4.595 | 4,346 | 508 | 11.69% |
07-19-2024 | $4.1901 | $4.7499 | $4.7499 | $4.1901 | 8,702 | 154 | 1.77% |
07-18-2024 | $4.4001 | $4.68 | $4.9 | $4.4 | 11,228 | 2,534 | 22.57% |
07-17-2024 | $4.63 | $4.87 | $4.92 | $4.3006 | 17,763 | 6,402 | 36.04% |
07-16-2024 | $4.2 | $4.77 | $4.89 | $4.18 | 30,518 | 5,288 | 17.33% |
07-15-2024 | $4.25 | $4.2399 | $4.3 | $4.165 | 11,544 | 633 | 5.48% |
07-12-2024 | $4.31 | $4.26 | $4.31 | $4.26 | 3,753 | 116 | 3.09% |
07-11-2024 | $4.27 | $4.25 | $4.35 | $4.2001 | 1,775 | 381 | 21.46% |
07-10-2024 | $4.47 | $4.27 | $4.47 | $4.21 | 8,392 | 2,171 | 25.87% |
07-09-2024 | $4.27 | $4.27 | $4.3999 | $4.25 | 3,144 | 408 | 12.98% |
07-08-2024 | $4.45 | $4.25 | $4.4999 | $4.23 | 3,317 | 1,974 | 59.51% |
07-05-2024 | $4.35 | $4.2967 | $4.43 | $4.21 | 2,309 | 550 | 23.82% |
07-03-2024 | $4.33 | $4.22 | $4.3477 | $4.21 | 3,159 | 601 | 19.03% |
07-02-2024 | $4.3056 | $4.21 | $4.3056 | $4.2 | 3,432 | 795 | 23.16% |
07-01-2024 | $4.27 | $4.39 | $4.41 | $4.152 | 1,953 | 282 | 14.44% |
06-28-2024 | $4.29 | $4.28 | $4.29 | $4.1527 | 7,003 | 378 | 5.4% |
News, Short Squeeze, Breakout and More Instantly...
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridipru...
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provid...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...